Dravet Syndrome (DS) - Market Insights, Epidemiology and Market Forecast to 2028

‘Dravet Syndrome (DS) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom),Japan, Australia and Austria.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Dravet Syndrome (DS) from 2017 to 2028 segmented by nine major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
Australia
Austria

Dravet Syndrome (DS) - Disease Understanding and Treatment Algorithm
The Dravet Syndrome (DS) market report gives the thorough understanding of the Dravet Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Dravet Syndrome in the US, Europe, Japan, Australia and Austria.

Dravet Syndrome Epidemiology
The Dravet Syndrome (DS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 9 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident population, incidence of Dravet Syndrome by Mutation Class, incidence of Dravet Syndrome by Mutation Type, seizure associated cases, gender-specific incident cases and age-specific incident cases) scenario of Dravet Syndrome (DS) in the 9MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan, Australia and Austria from 2017-2028.

According to the author, the total number of prevalent cases of Dravet Syndrome (DS) in 7 MM was found to be 36,301, in the year 2017.

Dravet Syndrome Drug Chapters
This segment of the Dravet Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment. Pharmacological management of Dravet syndrome focuses largely on the use antiepileptic drugs such as Valproic Acid, Clobazam, Topiramate, Levetiracetam, Zonisamide and Stiripentol. Detailed chapter for upcoming therapies like ZX008 (Zogenix) have been covered in the report.

Dravet Syndrome Market Outlook
The Dravet Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the author, the market of Dravet Syndrome in 9MM was found to be USD 112.88 million in 2017, and is expected to increase from 2017-2028.

Dravet Syndrome Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dravet Syndrome Report Insights

Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Dravet Syndrome Report Key Strengths

10 Year Forecast
9MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition

Dravet Syndrome Report Assessment

Current Treatment Practices
Unmet Needs
Detailed Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving Dravet Syndrome market
Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome market
To understand the future market competition in the Dravet Syndrome market.

1. Key Insights

2. Dravet Syndrome Market Overview at a Glance

2.1. Market Share (%) Distribution of Dravet Syndrome in 2017
2.2. Market Share (%) Distribution of Dravet Syndrome in 2028

3. Dravet Syndrome: Disease Background and Overview

3.1. Introduction
3.2. Clinical Features of Dravet Syndrome
3.2.1. Epilepsy
3.2.2. Cognition
3.2.3. Movement disorders
3.2.4. Sudden Death
3.3. Genetics of Dravet Syndrome
3.3.1. Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome
3.3.2. Functional aspects of voltage gate sodium channel mutations
3.3.3. Detection of SCN1A mutations
3.3.4. Inheritance mode and pattern
3.3.5. Dravet Syndrome without SCN1A Alterations
3.4. Signs and Symptoms of Dravet Syndrome
3.5. Pathophysiology
3.6. Diagnosis of Dravet Syndrome
3.6.1. Differential diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings
4.2. Total Incidence of Dravet Syndrome in 9MM

5. Country Wise-Epidemiology of Dravet Syndrome

6. United States

6.1. Assumptions and Rationale
6.2. Incident Population of Dravet Syndrome
6.3. Mutations associated with Dravet Syndrome
6.3.1. Incidence of Dravet Syndrome by Mutation Class
6.3.2. Incidence of Dravet Syndrome by Mutation Type
6.4. Seizure associated cases of Dravet Syndrome
6.5. Gender specific Incidence of Dravet Syndrome
6.6. Age specific Incidence of Dravet Syndrome
6.7. Mortality associated with Dravet Syndrome

7. EU-5

7.1. Assumptions and Rationale

8. Germany

8.1. Incident Population of Dravet Syndrome
8.2. Mutations associated with Dravet Syndrome
8.2.1. Incidence of Dravet Syndrome by Mutation Class
8.2.2. Incidence of Dravet Syndrome by Mutation Type
8.3. Seizure associated cases of Dravet Syndrome
8.4. Gender specific Incidence of Dravet Syndrome
8.5. Age specific Incidence of Dravet Syndrome
8.6. Mortality associated with Dravet Syndrome

9. France

9.1. Incident Population of Dravet Syndrome
9.2. Mutations associated with Dravet Syndrome
9.2.1. Incidence of Dravet Syndrome by Mutation Class
9.2.2. Incidence of Dravet Syndrome by Mutation Type
9.3. Seizure associated cases of Dravet Syndrome
9.4. Gender specific Incidence of Dravet Syndrome
9.5. Age specific Incidence of Dravet Syndrome
9.6. Mortality associated with Dravet Syndrome

10. Italy

10.1. Incident Population of Dravet Syndrome
10.2. Mutations associated with Dravet Syndrome
10.2.1. Incidence of Dravet Syndrome by Mutation Class
10.2.2. Incidence of Dravet Syndrome by Mutation Type
10.3. Seizure associated cases of Dravet Syndrome
10.4. Gender specific Incidence of Dravet Syndrome
10.5. Age specific Incidence of Dravet Syndrome
10.6. Mortality associated with Dravet Syndrome

11. Spain

11.1. Incident Population of Dravet Syndrome
11.2. Mutations associated with Dravet Syndrome
11.2.1. Incidence of Dravet Syndrome by Mutation Class
11.2.2. Incidence of Dravet Syndrome by Mutation Type.
11.3. Seizure associated cases of Dravet Syndrome
11.4. Gender specific Incidence of Dravet Syndrome
11.5. Age specific Incidence of Dravet Syndrome
11.6. Mortality associated with Dravet Syndrome

12. United Kingdom

12.1. Incident Population of Dravet Syndrome
12.2. Mutations associated with Dravet Syndrome
12.2.1. Incidence of Dravet Syndrome by Mutation Class
12.2.2. Incidence of Dravet Syndrome by Mutation Type
12.3. Seizure associated cases of Dravet Syndrome
12.4. Gender specific Incidence of Dravet Syndrome
12.5. Age specific Incidence of Dravet Syndrome
12.6. Mortality associated with Dravet Syndrome

13. Austria

13.1. Incident Population of Dravet Syndrome
13.2. Mutations associated with Dravet Syndrome
13.2.1. Incidence of Dravet Syndrome by Mutation Class
13.2.2. Incidence of Dravet Syndrome by Mutation Type
13.3. Seizure associated cases of Dravet Syndrome
13.4. Gender specific Incidence of Dravet Syndrome
13.5. Age specific Incidence of Dravet Syndrome
13.6. Mortality associated with Dravet Syndrome

14. Japan

14.1. Assumptions and Rationale
14.2. Incident Population of Dravet Syndrome
14.3. Mutations associated with Dravet Syndrome
14.3.1. Incidence of Dravet Syndrome by Mutation Class
14.3.2. Incidence of Dravet Syndrome by Mutation Type
14.4. Seizure associated cases of Dravet Syndrome
14.5. Gender specific Incidence of Dravet Syndrome
14.6. Age specific Incidence of Dravet Syndrome
14.7. Mortality associated with Dravet Syndrome

15. Australia

15.1. Assumptions and Rationale
15.2. Incident Population of Dravet Syndrome
15.3. Mutations associated with Dravet Syndrome
15.3.1. Incidence of Dravet Syndrome by Mutation Class
15.3.2. Incidence of Dravet Syndrome by Mutation Type
15.4. Seizure associated cases of Dravet Syndrome
15.5. Gender specific Incidence of Dravet Syndrome
15.6. Age specific Incidence of Dravet Syndrome
15.7. Mortality associated with Dravet Syndrome

16. Treatment of Dravet Syndrome

16.1. Current Treatment Practices
16.1.1. First-Line Therapies: Valproic Acid and Clobazam
16.1.2. Second-Line Therapies
16.1.3. Third Line of Therapies
16.2. Treatment Algorithm

17. Unmet Needs

18. Marketed Drugs

18.1. Diacomit: Biocodex
18.1.1. Drug Description
18.1.2. Mechanism of Action
18.1.3. Regulatory Milestones
18.1.4. Advantages & Disadvantages
18.1.5. Safety and Efficacy
18.1.6. Product Profile
18.2. Epidiolex: GW Pharmaceuticals
18.2.1. Drug Description
18.2.2. Mechanism of Action
18.2.3. Regulatory Milestones
18.2.4. Advantages & Disadvantages
18.2.5. Safety and Efficacy
18.2.6. Product Profile

19. Emerging Therapies

19.1. FINTEPLA: Zogenix
19.1.1. Product Description
19.1.2. Other Developmental Activities
19.1.3. Regulatory Milestones
19.1.4. Clinical Development
19.1.5. Safety and Efficacy
19.1.6. Product Profile

20. Dravet Syndrome: 9 Major Market Analysis

20.1. Key Findings
20.2. Total Market Size of Dravet Syndrome in 9MM
20.3. 9 MM Size of Dravet Syndrome by Line of Treatment

21. Market Outlook by Country

21.1. The United States: Market Outlook
21.2. United States Market Size
21.2.1. Total Market Size of Dravet Syndrome
21.2.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
21.3. EU-6 Countries: Market Outlook
21.4. Germany Market Size
21.4.1. Total Market Size of Dravet Syndrome
21.4.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
21.5. France Market Size
21.5.1. Total Market Size of Dravet Syndrome
21.5.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
21.6. Italy Market Size
21.6.1. Total Market Size of Dravet Syndrome
21.6.2. Dravet Syndrome Market Size by by Line of Treatment (LoT)
21.7. Spain Market Size
21.7.1. Total Market Size of Dravet Syndrome
21.7.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
21.8. The United Kingdom Market Size
21.8.1. Total Market Size of Dravet Syndrome
21.8.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
21.9. Austria Market Size
21.9.1. Total Market Size of Dravet Syndrome
21.9.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
21.10. Japan: Market Outlook
21.11. Japan: Market Size
21.11.1. Total Market Size of Dravet Syndrome
21.11.2. Dravet Syndrome Market Size by Line of Treatment (LoT)

22. Market Drivers23. Market Barriers24. Appendix

25. Report Methodology

25.1. Sources Used

26. Capabilities27. Disclaimer28. About the Author

List of Tables

Table 1: Stages of Dravet Syndrome
Table 2: Genetic background of Dravet syndrome
Table 3: Total Incident Population of Dravet Syndrome in 9MM (2017-2028)
Table 4: Incident Population of Dravet Syndrome in the United States (2017-2028)
Table 5: Mutation positive cases of Dravet Syndrome in the United States (2017-2028)
Table 6: Incidence of Dravet Syndrome by Mutation Class in the United States (2017-2028)
Table 7: Incidence of Dravet Syndrome by Mutation Type in the United States (2017-2028)
Table 8: Seizure associated cases of Dravet Syndrome in the United States (2017-2028)
Table 9: Gender specific Incidence of Dravet Syndrome in the United States (2017-2028)
Table 10: Age specific Incidence of Dravet Syndrome in the United States (2017-2028)
Table 11: Number of Deaths Associated with Dravet Syndrome in the United States (2017-2028)
Table 12: Incident Population of Dravet Syndrome in Germany (2017-2028)
Table 13: Mutation positive cases of Dravet Syndrome in Germany (2017-2028)
Table 14: Incidence of Dravet Syndrome by Mutation Class in Germany (2017-2028)
Table 15: Incidence of Dravet Syndrome by Mutation Type in Germany (2017-2028)
Table 16: Seizure associated cases of Dravet Syndrome in Germany (2017-2028)
Table 17: Gender specific Incidence of Dravet Syndrome in Germany (2017-2028)
Table 18: Age specific Incidence of Dravet Syndrome in Germany (2017-2028)
Table 19: Number of Deaths Associated with Dravet Syndrome in Germany (2017-2028)
Table 20: Incident Population of Dravet Syndrome in France (2017-2028)
Table 21: Mutation positive cases of Dravet Syndrome in France (2017-2028)
Table 22: Incidence of Dravet Syndrome by Mutation Class in France (2017-2028)
Table 23: Incidence of Dravet Syndrome by Mutation Type in France (2017-2028)
Table 24: Seizure associated cases of Dravet Syndrome in France (2017-2028)
Table 25: Gender specific Incidence of Dravet Syndrome in France (2017-2028)
Table 26: Age specific Incidence of Dravet Syndrome in France (2017-2028)
Table 27: Number of Deaths Associated with Dravet Syndrome in France (2017-2028)
Table 28: Incident Population of Dravet Syndrome in Italy (2017-2028)
Table 29: Mutation positive cases of Dravet Syndrome in Italy (2017-2028)
Table 30: Incidence of Dravet Syndrome by Mutation Class in Italy (2017-2028)
Table 31: Incidence of Dravet Syndrome by Mutation Type in Italy (2017-2028)
Table 32: Seizure associated cases of Dravet Syndrome in Italy (2017-2028)
Table 33: Gender specific Incidence of Dravet Syndrome in Italy (2017-2028)
Table 34: Age specific Incidence of Dravet Syndrome in Italy (2017-2028)
Table 35: Number of Deaths Associated with Dravet Syndrome in Italy (2017-2028)
Table 36: Incident Population of Dravet Syndrome in Spain (2017-2028)
Table 37: Mutation positive cases of Dravet Syndrome in Spain (2017-2028)
Table 38: Incidence of Dravet Syndrome by Mutation Class in Spain (2017-2028)
Table 39: Incidence of Dravet Syndrome by Mutation Type in Spain (2017-2028)
Table 40: Seizure associated cases of Dravet Syndrome in Spain (2017-2028)
Table 41: Gender specific Incidence of Dravet Syndrome in Spain (2017-2028)
Table 42: Age specific Incidence of Dravet Syndrome in Spain (2017-2028)
Table 43: Number of Deaths Associated with Dravet Syndrome in Spain (2017-2028)
Table 44: Incident Population of Dravet Syndrome in the United Kingdom (2017-2028)
Table 45: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017-2028)
Table 46: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017-2028)
Table 47: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017-2028)
Table 48: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017-2028)
Table 49: Gender specific Incidence of Dravet Syndrome in the United Kingdom (2017-2028)
Table 50: Age specific Incidence of Dravet Syndrome in the United Kingdom (2017-2028)
Table 51: Number of Deaths Associated with Dravet Syndrome in the United Kingdom (2017-2028)
Table 52: Incident Population of Dravet Syndrome in Austria (2017-2028)
Table 53: Mutation positive cases of Dravet Syndrome in Austria (2017-2028)
Table 54: Incidence of Dravet Syndrome by Mutation Class in Austria (2017-2028)
Table 55: Incidence of Dravet Syndrome by Mutation Type in Austria (2017-2028)
Table 56: Seizure associated cases of Dravet Syndrome in Austria (2017-2028)
Table 57: Gender specific Incidence of Dravet Syndrome in Austria (2017-2028)
Table 58: Age specific Incidence of Dravet Syndrome in Austria (2017-2028)
Table 59: Number of Deaths Associated with Dravet Syndrome in Austria (2017-2028)
Table 60: Incident Population of Dravet Syndrome in Japan (2017-2028)
Table 61: Mutation positive cases of Dravet Syndrome in Japan (2017-2028)
Table 62: Incidence of Dravet Syndrome by Mutation Class in Japan (2017-2028)
Table 63: Incidence of Dravet Syndrome by Mutation Type in Japan (2017-2028)
Table 64: Seizure associated cases of Dravet Syndrome in Japan (2017-2028)
Table 65: Gender specific Incidence of Dravet Syndrome in Japan (2017-2028)
Table 66: Age specific Incidence of Dravet Syndrome in Japan (2017-2028)
Table 67: Number of Deaths Associated with Dravet Syndrome in Japan (2017-2028)
Table 68: Incident Population of Dravet Syndrome in Australia (2017-2028)
Table 69: Mutation positive cases of Dravet Syndrome in Australia (2017-2028)
Table 70: Incidence of Dravet Syndrome by Mutation Class in Australia (2017-2028)
Table 71: Incidence of Dravet Syndrome by Mutation Type in Australia (2017-2028)
Table 72: Seizure associated cases of Dravet Syndrome in Australia (2017-2028)
Table 73: Gender specific Incidence of Dravet Syndrome in Australia (2017-2028)
Table 74: Age specific Incidence of Dravet Syndrome in Australia (2017-2028)
Table 75: Number of Deaths Associated with Dravet Syndrome in Australia (2017-2028)
Table 76: ZX008 Clinical Trial Description, 2019
Table 77: TAK-935, Clinical Trial Description, 2019
Table 78: 9 Major Market Size of Dravet Syndrome in USD Million (2017-2028)
Table 79: 9MM Size of Dravet Syndrome by LoT in USD Million (2017-2028)
Table 80: The US Market Dravet Syndrome in USD Million (2017-2028)
Table 81: The US Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Table 82: Germany Market of Dravet Syndrome in USD Million (2017-2028)
Table 83: Germany Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Table 84: France Market of Dravet Syndrome in USD Million (2017-2028)
Table 85: France Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Table 86: Italy Market of Dravet Syndrome in USD Million (2017-2028)
Table 87: Italy Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Table 88: Spain Market of Dravet Syndrome in USD Million (2017-2028)
Table 89: Spain Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Table 90: UK Market of Dravet Syndrome in USD Million (2017-2028)
Table 91: UK Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Table 92: Austria Market of Dravet Syndrome in USD Million (2017-2028)
Table 93: Austria Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Table 94: Japan Market of Dravet Syndrome in USD Million (2017-2028)
Table 95: Japan Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Table 96: Australia Market of Dravet Syndrome in USD Million (2017-2028)
Table 97:Australia Dravet Syndrome Market Size by LoT in USD Million (2017-2028)

List of Figures

Figure 1: Schematic representation of clinical manifestations of Dravet syndrome
Figure 2: Differential diagnosis of Dravet syndrome in the course of the disease
Figure 3: Total Incident Population of Dravet Syndrome in 9 MM (2017-2028)
Figure 4: Incident Population of Dravet Syndrome in the United States (2017-2028)
Figure 5: Mutation positive cases of Dravet Syndrome in the United States (2017-2028)
Figure 6: Incidence of Dravet Syndrome by Mutation Class in the United States (2017-2028)
Figure 7: Incidence of Dravet Syndrome by Mutation Type in the United States (2017-2028)
Figure 8: Seizure associated cases of Dravet Syndrome in the United States (2017-2028)
Figure 9: Gender specific Incidence of Dravet Syndrome in the United States (2017-2028)
Figure 10: Age specific Incidence of Dravet Syndrome in the United States (2017-2028)
Figure 11: Number of Deaths Associated with Dravet Syndrome in the United States (2017-2028)
Figure 12: Incident Population of Dravet Syndrome in Germany (2017-2028)
Figure 13: Mutation positive cases of Dravet Syndrome in Germany (2017-2028)
Figure 14: Incidence of Dravet Syndrome by Mutation Class in Germany (2017-2028)
Figure 15: Incidence of Dravet Syndrome by Mutation Type in Germany (2017-2028)
Figure 16: Seizure associated cases of Dravet Syndrome in Germany (2017-2028)
Figure 17: Gender specific Incidence of Dravet Syndrome in Germany (2017-2028)
Figure 18: Age specific Incidence of Dravet Syndrome in Germany 2017-2028)
Figure 19: Number of Deaths Associated with Dravet Syndrome in Germany (2017-2028)
Figure 20: Incident Population of Dravet Syndrome in France (2017-2028)
Figure 21: Mutation positive cases of Dravet Syndrome in France (2017-2028)
Figure 22: Incidence of Dravet Syndrome by Mutation Class in France (2017-2028)
Figure 23: Incidence of Dravet Syndrome by Mutation Type in France (2017-2028)
Figure 24: Seizure associated cases of Dravet Syndrome in France (2017-2028)
Figure 25: Gender specific Incidence of Dravet Syndrome in France (2017-2028)
Figure 26: Age specific Incidence of Dravet Syndrome in France (2017-2028)
Figure 27: Number of Deaths Associated with Dravet Syndrome in France (2017-2028)
Figure 28: Incident Population of Dravet Syndrome in Italy (2017-2028)
Figure 29: Mutation positive cases of Dravet Syndrome in Italy (2017-2028)
Figure 30: Incidence of Dravet Syndrome by Mutation Class in Italy (2017-2028)
Figure 31: Incidence of Dravet Syndrome by Mutation Type in Italy (2017-2028)
Figure 32: Seizure associated cases of Dravet Syndrome in Italy (2017-2028)
Figure 33: Gender specific Incidence of Dravet Syndrome in Italy (2017-2028)
Figure 34: Age specific Incidence of Dravet Syndrome in Italy (2017-2028)
Figure 35: Number of Deaths Associated with Dravet Syndrome in Italy (2017-2028)
Figure 36: Incident Population of Dravet Syndrome in Spain (2017-2028)
Figure 37: Mutation positive cases of Dravet Syndrome in Spain (2017-2028)
Figure 38: Incidence of Dravet Syndrome by Mutation Class in Spain (2017-2028)
Figure 39: Incidence of Dravet Syndrome by Mutation Type in Spain (2017-2028)
Figure 40: Seizure associated cases of Dravet Syndrome in Spain (2017-2028)
Figure 41: Gender specific Incidence of Dravet Syndrome in Spain (2017-2028)
Figure 42: Age specific Incidence of Dravet Syndrome in Spain (2017-2028)
Figure 43: Number of Deaths Associated with Dravet Syndrome in Spain (2017-2028)
Figure 44: Incident Population of Dravet Syndrome in the United Kingdom (2017-2028)
Figure 45: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017-2028)
Figure 46: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017-2028)
Figure 47: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017-2028)
Figure 48: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017-2028)
Figure 49: Gender specific Incidence of Dravet Syndrome in the United Kingdom (2017-2028)
Figure 50: Age specific Incidence of Dravet Syndrome in the United Kingdom (2017-2028)
Figure 51: Number of Deaths Associated with Dravet Syndrome in the United Kingdom (2017-2028)
Figure 52: Incident Population of Dravet Syndrome in Austria (2017-2028)
Figure 53: Mutation positive cases of Dravet Syndrome in Austria (2017-2028)
Figure 54: Incidence of Dravet Syndrome by Mutation Class in Austria (2017-2028)
Figure 55: Incidence of Dravet Syndrome by Mutation Type in Austria (2017-2028)
Figure 56: Seizure associated cases of Dravet Syndrome in Austria (2017-2028)
Figure 57: Gender specific Incidence of Dravet Syndrome in Austria (2017-2028)
Figure 58: Age specific Incidence of Dravet Syndrome in Austria (2017-2028)
Figure 59: Number of Deaths Associated with Dravet Syndrome in Austria (2017-2028)
Figure 60: Incident Population of Dravet Syndrome in Japan (2017-2028)
Figure 61: Mutation positive cases of Dravet Syndrome in Japan (2017-2028)
Figure 62: Incidence of Dravet Syndrome by Mutation Class in Japan (2017-2028)
Figure 63: Incidence of Dravet Syndrome by Mutation Type in Japan (2017-2028)
Figure 64: Seizure associated cases of Dravet Syndrome in Japan (2017-2028)
Figure 65: Gender specific Incidence of Dravet Syndrome in Japan (2017-2028)
Figure 66: Age specific Incidence of Dravet Syndrome in Japan (2017-2028)
Figure 67: Number of Deaths Associated with Dravet Syndrome in Japan (2017-2028)
Figure 68: Incident Population of Dravet Syndrome in Australia (2017-2028)
Figure 69: Mutation positive cases of Dravet Syndrome in Australia (2017-2028)
Figure 70: Incidence of Dravet Syndrome by Mutation Class in Australia (2017-2028)
Figure 71: Incidence of Dravet Syndrome by Mutation Type in Australia (2017-2028)
Figure 72: Seizure associated cases of Dravet Syndrome in Australia (2017-2028)
Figure 73: Gender specific Incidence of Dravet Syndrome in Australia (2017-2028)
Figure 74: Age specific Incidence of Dravet Syndrome in Australia (2017-2028)
Figure 75: Number of Deaths Associated with Dravet Syndrome in Australia (2017-2028)
Figure 76: Treatment algorithm of epilepsy in Dravet syndrome.
Figure 77: Unmet Needs for Dravet Syndrome
Figure 78: 9 Major Market Size of Dravet Syndrome in USD Million (2017-2028)
Figure 79: 9 Major Market Size of Dravet Syndrome by Line of Treatment in USD Million (2017-2028)
Figure 80: Market Size of Dravet Syndrome in the United States, USD Millions (2017-2028)
Figure 81: The U.S. Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Figure 82: Market Size of Dravet Syndrome in the Germany, USD Millions (2017-2028)
Figure 83: Germany Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Figure 84: Market Size of Dravet Syndrome in France, USD Millions (2017-2028)
Figure 85: France Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
Figure 86: Market Size of Dravet Syndrome in Italy, USD Millions (2017-2028)
Figure 87: Italy Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
Figure 88: Market Size of Dravet Syndrome in Spain, USD Millions (2017-2028)
Figure 89: Spain Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
Figure 90: Market Size of Dravet Syndrome in UK, USD Millions (2017-2028)
Figure 91: The UK Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
Figure 92: Market Size of Dravet Syndrome in Austria, USD Millions (2017-2028)
Figure 93: Austria Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
Figure 94: Market Size of Dravet Syndrome in Japan, USD Millions (2017-2028)
Figure 95: Japan Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Figure 96: Market Size of Dravet Syndrome in Australia, USD Millions (2017-2028)
Figure 97: Australia Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
Figure 98: Market Drivers of Dravet Syndrome
Figure 99:Market Barriers of Dravet Syndrome